Balance Sheet
Includes Current Assets, Liabilities and Stockholder's Equity
Latest Financial Results
Q4 & FY 2023
Fiscal Year Ended Dec 31, 2023
$0.2M
Revenue for the three months and year ended December 31, 2023, was $0.2 million and $60.3 million, respectively, compared to $11.0 million and $27.1 million for the same periods in 2022
$143.9M
As of December 31, 2023, Adaptimmune had cash and cash equivalents of $143.9 million and Total Liquidity1 of $146.9 million, compared to $108.0 million and $204.6 million, respectively, as of December 31, 2022.
1Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below.
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2023
Report Links
For complete information regarding our financials, see our periodic filings